EUVIMEDEUVIMED entdecken
Netzwerk-MetaanalyseSystematische ÜbersichtOpen Access · CC BY 4.0

The Efficacy and Safety of Four Novel PCSK9 Monoclonal Antibodies in Patients With Hypercholesterolemia: A Systematic Review With Network Meta‐Analysis and Trial Sequential Analysis

Sihua Wang iD, Chenyu Li iD, Duncong Fan iD

Cardiovascular Therapeutics · 2026-01 · 2026 (1)

DOI: 10.1155/cdr/6345873 ↗

Kurz gefasst

Netzwerk-Metaanalyse in der Zeitschrift Cardiovascular Therapeutics, online erschienen am 24.01.2026. Verfasst von Sihua Wang und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Haining People's Hospital (The Affiliated Haining Hospital of Jiaxing University), Haining, China. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Anticholesteremic Agents, Cholesterol, LDL, Hypercholesterolemia. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

This network meta‐analysis (NMA) evaluated four novel proprotein convertase subtilisin/kexin type 9 (PCSK9) monoclonal antibodies for hypercholesterolemia management, comparing their lipid‐lowering efficacy and safety.

Methods

We systematically identified randomized controlled trials employing the frequentist NMA method to assess reductions in low‐density lipoprotein cholesterol (LDL‐C), apolipoprotein B (ApoB), and lipoprotein (a) (Lp[a]), alongside treatment‐emergent adverse events (TEAEs) and serious TEAEs. P ‐scores ranked therapeutic hierarchies, with meta‐regression and subgroup analyses exploring heterogeneity. Trial sequential analysis determined the adequacy of cumulative evidence. Confidence in the network meta‐analysis approach was used to evaluate the confidence in the findings from NMA.

Results

A total of eight trials with 3,975 Chinese patients were included. Ongericimab 150 mg every 2 weeks (Q2W) ranked first in all efficacy outcomes, demonstrating pronounced effects in LDL‐C, ApoB, and Lp(a) reduction versus placebo, with mean differences of −74.21% (95% confidence interval [CI]: −79.69% to −68.73%), −64.36% (95% CI: −68.58% to −60.13%), and −50.93% (95% CI: −56.24% to −45.61%), respectively. All interventions exhibited safety profiles comparable with placebo, with no significant differences in TEAEs or serious TEAEs incidence. The analyses suggested that a portion of the evidence base was robust and reliable.

Conclusion

These findings positioned ongericimab 150 mg Q2W as a clinically optimal PCSK9 inhibitor with robust lipid‐lowering capacity. The results highlight the potential of next‐generation PCSK9 monoclonal antibodies, particularly in East Asian populations, while underscoring the need for large‐scale multinational trials to validate ethnic‐specific responses.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, MonoclonalAnticholesteremic AgentsCholesterol, LDLHypercholesterolemiaPCSK9 InhibitorsSerine Proteinase InhibitorsAgedFemaleHumansMaleMiddle AgedAntibodies, Monoclonal, HumanizedBiomarkersLipoprotein(a)Proprotein Convertase 9Randomized Controlled Trials as TopicTreatment OutcomeApolipoprotein B-100

Stichwörter der Autor:innen

ebronucimabhypercholesterolemianetwork meta-analysisongericimabrecaticimabtafolecimab

Substanzen

Antibodies, MonoclonalAntibodies, Monoclonal, HumanizedAnticholesteremic AgentsAPOB protein, humanBiomarkersCholesterol, LDLLipoprotein(a)LPA protein, humanPCSK9 InhibitorsPCSK9 protein, human

Autor:innen und Institutionen

  • Department of Pharmacy, Haining People's Hospital (The Affiliated Haining Hospital of Jiaxing University), Haining, China.
  • Department of Pharmacy, Haining Hospital of Traditional Chinese Medicine, Haining, Zhejiang, China.

ORCID-Profile: Sihua Wang, Chenyu Li, Duncong Fan

Zitieren

APA

Wang, S., Li, C., & Fan, D. (2026). The Efficacy and Safety of Four Novel PCSK9 Monoclonal Antibodies in Patients With Hypercholesterolemia: A Systematic Review With Network Meta‐Analysis and Trial Sequential Analysis. Cardiovascular Therapeutics, 2026(1). https://doi.org/10.1155/cdr/6345873

Vancouver

Wang S, Li C, Fan D. The Efficacy and Safety of Four Novel PCSK9 Monoclonal Antibodies in Patients With Hypercholesterolemia: A Systematic Review With Network Meta‐Analysis and Trial Sequential Analysis. Cardiovascular Therapeutics. 2026;2026(1). doi:10.1155/cdr/6345873

BibTeX
@article{Wang2026,
  author = {Wang, Sihua and Li, Chenyu and Fan, Duncong},
  title = {The Efficacy and Safety of Four Novel PCSK9 Monoclonal Antibodies in Patients With Hypercholesterolemia: A Systematic Review With Network Meta‐Analysis and Trial Sequential Analysis},
  journal = {Cardiovascular Therapeutics},
  year = {2026},
  volume = {2026},
  number = {1},
  doi = {10.1155/cdr/6345873}
}
Kostenlos starten →